Phase 1 trial investigates dosing regimens of cenobamate for safety and efficacy in adolescents with focal epilepsy, indicating optimized treatment approaches.
To report the pharmacokinetics (PK) of cenobamate single- and multiple-dose regimens in the adolescent subgroup of patients (12 to <18 years old) from the open-label clinical studies (Study C039 [NCT04903314] and Study C040 [NCT05067634]) in pediatric patients (2 to <18 years old) with focal seizures.
No takes yet. Share an insight, caveat, or question.
Vashi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: